A meta-analysis reported that TET2 mutations negatively affect the prognosis of patients with normal karyotype (NK)-AML, while the prognostic implications of IDH1/2 mutations in patients with NK-AML are unclear [14, 15]. This evidence concerns the gene TET2 and acute myeloid leukemia.